← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Manning Paul B
10% Owner | Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001494695
Purchase history
- Companies traded
- 3
- Purchases · 12M
- 2
- Purchases · 24M
- 5
- Average purchase
- $7.5M
- Median purchase
- $5.2M
- Gross purchase value
- $30.1M
Companies: Candel Therapeutics, Inc. | Taysha Gene Therapies, Inc. | Verrica Pharmaceuticals Inc.
5 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-02-26 | Candel Therapeutics, Inc. | CADL | Director | $3.0M | Open filing |
| 2025-11-25 | Verrica Pharmaceuticals Inc. | VRCA | Director | 10% Owner | $17.5M | Open filing |
| 2025-06-03 | Taysha Gene Therapies, Inc. | TSHA | 10% Owner | $2.1M | Open filing |
| 2024-12-18 | Candel Therapeutics, Inc. | CADL | Director | $7.5M | Open filing |
| 2024-11-26 | Verrica Pharmaceuticals Inc. | VRCA | Director | 10% Owner | — | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 1/2
- Large purchase ≥ $100k
- 4/4
- Cluster buying · 15D
- 2/5
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.